{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Increased abs. NKG2D+CD3+CD8 Tcells"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Increased abs. NKG2D+CD3-CD56+ T cells"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"* Isolate CD3+CD8+ and CD8+CD56+ from patients' blood following transplant.\n* Identify NKG2D and DAP10 expression.\n* Determine the mechanism of tumor cell killing and the relationship to NKG2D or DAP 10 expression.\n\nAfter isolating CD8+ cells from patient's blood samples using the AutoMACS, we will evaluate the expression of NKG2D and DAP10 on all CD8+ cells (CD3+CD8+ and CD8+CD56+cells) pre-transplant (Baseline) and following the third and fourth cellular infusions using phenotypic analysis. We postulate the increased expression of both DAP10 and NKG2D on the CD8 population immediately following APSCT and effector cell infusions when compared to baseline.","groups":[{"description":"Infusing IL-2 and GM-CSF post-Hematopoietic Stem Cell Transplant (HSCT)\n\nEx-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.","id":"OG000","title":"Ex-vivo Expanded Effector Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Sixteen out of nineteen participants samples were analyzed. Three participants' samples were not available for analysis.","reportingStatus":"POSTED","timeFrame":"Pre-transplant and following the third and fourth cellular infusions","title":"Number of Participants With Increased Expression of DAP10 and NKG2D on the CD8 Cell Population","type":"SECONDARY","unitOfMeasure":"Participants"}